Farxiga, a Type 2 diabetes medication marketed by Astra Zeneca, may be associated with an increased risk of diabetic ketoacidosis (DKA), a dangerous condition caused by excess ketones (acid) in the blood. Less than two years after its approval in the U.S., the Food & Drug Administration (FDA) was reviewing the safety of Farxiga and other sodium-glucose cotransporter-2 (SGLT2) inhibitors, after it had received numerous reports linking these drugs to this potentially life-threatening disorder. Farxiga patients who develop diabetic ketoacidosis are at risk for diabetic coma and even death.
You may be entitled to compensation for any injury-related damages you incurred if you or a loved one took Farxiga and were hospitalized following a diagnosis of diabetic ketoacidosis, ketoacidosis, acidosis or ketosis. The nationwide law firm of Bernstein Liebhard LLP is investigating the potential association between SGLT2 inhibitors and ketoacidosis. To learn whether you might be eligible to file a Farxiga lawsuit, please contact our office today by calling .
The FDA approved Farxiga (dapagliflozin) in January 2014, making it the second SGLT2 inhibitor cleared for sale in the U.S. Astra Zeneca’s Xigduo XR, a combination of dapagliflozin and metformin, was approved by the agency in October 2014. Both medications are used in conjunction with diet and exercise to lower blood sugar in Type 2 diabetics. Dapagliflozin accomplishes this by blocking resorption of glucose in the kidneys, leading to an increase in urinary glucose excretion.
In May 2012, the FDA announced that it was investigating Farxiga, Xigduo XR and other SGLT inhibitors after it had received 20 reports of acidosis (reported as diabetic ketoacidosis (DKA), ketoacidosis, or ketosis) in patients using the medications. All of the cases occurred between March 2013 and June 6, 2014, and required emergency room visits or hospitalization. Since then, the FDA has continued to receive reports of ketoacidosis occurring in patients using SGLT inhibitors.
The FDA will now try to determine if new information regarding diabetic ketoacidosis should be added to the labels of Farxiga and other SGLT2 inhibitors. In the meantime, the agency has advised patients to be aware of the signs and symptoms associated with ketosis, which include:
Patients should not stop or change their diabetes medicines without first talking to their prescriber. However, the FDA has advised healthcare providers to discontinue treatment with SGLT2 inhibitors if acidosis is confirmed.
Compensation to cover medical bills, lost wages, pain and suffering, and other damages may be available to alleged victims of Farxiga-induced ketoacidosis. To learn more about the process of filing a Farxiga lawsuit, please contact Bernstein Liebhard LLP today by calling .